Timothy M. Cox, Ph.D.
Affiliations: | Medicine | University of Cambridge, Cambridge, England, United Kingdom |
Area:
lysosomal storage disordersWebsite:
http://www.sid.cam.ac.uk/aboutus/people/person.html?crsid=tmc12Google:
"Timothy Cox"Mean distance: 9.18 | S | N | B | C | P |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Beck M, Cox TM. (2019) Comment: Why are females with Fabry disease affected? Molecular Genetics and Metabolism Reports. 21: 100529 |
Pavlova EV, Shatunov A, Wartosch L, et al. (2019) The lysosomal disease caused by mutant VPS33A. Human Molecular Genetics |
Serratrice C, Cox TM, Leguy-Seguin V, et al. (2019) Splenic Artery Aneurysms, A Rare Complication of Type 1 Gaucher Disease: Report of Five Cases. Journal of Clinical Medicine. 8 |
Weinreb NJ, Cox TM, Mistry PK, et al. (2019) Biomarker Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials Blood. 134: 4859-4859 |
Donald A, Jones SA, Vellodi A, et al. (2019) From birth to the sixth decade - A natural history study of 42 patients with neuronopathic Gaucher disease Molecular Genetics and Metabolism. 126 |
Cox TM, Charrow J, Lukina E, et al. (2019) Effects of oral eliglustat on skeletal manifestations in patients with type 1 Gaucher disease: Results from four completed clinical trials after long-term treatment Molecular Genetics and Metabolism. 126 |
Pohl S, Angermann A, Jeschke A, et al. (2018) The lysosomal protein arylsulfatase B is a key enzyme involved in skeletal turnover. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research |
Cachon-Gonzalez MB, Zaccariotto E, Cox TM. (2018) Genetics and Therapies for GM2 Gangliosidosis. Current Gene Therapy |
Mistry PK, Charrow J, Cox T, et al. (2018) Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials Blood. 132: 2396-2396 |
Smith NJC, Fuller M, Saville JT, et al. (2017) Reduced cerebral vascularisation in experimental neuronopathic Gaucher disease. The Journal of Pathology |